

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A process for the preparation of a dry powder inhaler which comprises exposing, during manufacture, a dry powder inhaler optionally filled with a powder formulation, or one or more components thereof, to a gas at low pressure.
2. (Original) A process according to claim 1 where the gas is air.
3. (Currently amended) A process according to claim 1~~or 2~~ where the pressure is less than 200 mbar.
4. (Currently amended) A process according to ~~any one of claims 1 to 3~~ claim 1 where the pressure is less than 100 mbar.
5. (Currently amended) A process according to ~~any one of claims 1 to 4~~ claim 1 where the inhaler is Turbuhaler.
6. (Currently amended) A process according to ~~any one of claims 1 to 5~~ claim 1 where the powder formulation comprises one or more drugs and one or more pharmaceutically acceptable carriers or excipients.
7. (Currently amended) A process according to ~~any one of claims 1 to 5~~ claim 1 where the powder formulation comprises one or more drugs selected from the group consisting of: drug is

mometasone (~~e.g. as furoate~~), ciclesonide, zoticasone, flumoxonide, fluticasone (~~e.g. as 17-propionate~~) budesonide, salmeterol (~~e.g. as xinafoate~~) and formoterol (~~e.g. as fumarate dihydrate~~) or ~~tiotropium~~ tiotropium bromide.

8. (Currently amended) A process according to ~~any one of claims 1 to 5~~ claim 1 where the powder formulation comprises one or more drug~~s are~~ combinations selected from the group consisting of fluticasone propionate/salmeterol xinafoate, ciclesonide/formoterol fumarate dihydrate, mometasone furoate/formoterol fumarate dihydrate, budesonide/formoterol fumarate dihydrate, fluticasone propionate/formoterol fumarate dihydrate and tiotropium bromide/formoterol fumarate dihydrate.

9. (Currently amended) A process according to ~~any one of claims 1 to 5~~ claim 1 where the powder formulation comprises one or more drug~~s are~~ combinations selected from the group consisting of, budesonide and formoterol fumarate dihydrate.

10. (Original) A process for reducing electrostatic charges from one or more inhaler components, or a complete inhaler, optionally filed with a powder formulation, the process comprising:

- i) placing one or more inhaler components, or a complete inhaler, optionally filed with a powder formulation in a chamber,
- ii) reducing the pressure of gas in the chamber,
- iii) returning the pressure to atmospheric pressure
- iv) optionally repeating steps ii) and iii)

11. (Currently amended) A dry powder inhaler prepared according to the process of ~~any one of claims 1 to 10~~ claim 1.

12. (New) The process of claim 7, wherein the mometasone is furoate.

Applicant : Magnus Olsson et al.
Serial No. : To Be Assigned
Filed : Herewith
Page : 5 of 6

Attorney's Docket No.: 06275-506US1 / 101245-1P US

13. (New) The process of claim 7, wherein the fluticasone is 17-propionate.
14. (New) The process of claim 7, wherein the salmeterol is xinafoate.
15. (New) The process of claim 7, wherein the formoterol is fumarate dihydrate.